Childhood Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Option Overview
There are different types of treatment for children with non-Hodgkin lymphoma. Different types of treatment are available for children with non-Hodgkin lymphoma. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Because cancer in children is rare, taking part in a clinical trial should be considered. Some clinical trials are open only to patients who have not started treatment. Children with non-Hodgkin lymphoma should have their treatment planned by a team of doctors with expertise in treating childhood cancer.Treatment will be overseen by a pediatric oncologist, a doctor who specializes in treating children with cancer. The pediatric
Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment for Diffuse, Small Noncleaved-Cell / Burkitt Lymphoma
Diffuse, small, noncleaved-cell/Burkitt lymphoma typically involves younger patients and represents the most common type of pediatric NHL.Standard Treatment Options for Diffuse, Small Noncleaved-Cell/Burkitt LymphomaStandard treatment options for diffuse, small, noncleaved-cell/Burkitt lymphoma include the following:Aggressive multidrug regimens.Central nervous system (CNS) prophylaxis.Aggressive multidrug regimensStandard treatment for diffuse, small, noncleaved-cell/Burkitt lymphoma is usually with aggressive multidrug regimens similar to those used for the advanced-stage aggressive lymphomas (such as diffuse large cell).[2,3,4] In some institutions, treatment includes the use of consolidative bone marrow transplantation.[5,6] Adverse prognostic factors include bulky abdominal disease and high serum lactate dehydrogenase.Evidence (aggressive multidrug regimens):An intensive clinical trial (CLB-9251 [NCT00002494]) used aggressive combination chemotherapy patterned after that used
Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Non-Hodgkin Lymphoma During Pregnancy
General Information About NHL During PregnancyNon-Hodgkin lymphomas (NHLs) occur more frequently than Hodgkin lymphoma in an older population. This age difference may account for fewer reports of NHL in pregnant patients.Stage Information for NHL During PregnancyTo avoid exposure to ionizing radiation, magnetic resonance imaging is the preferred tool for staging evaluation. (Refer to the Stage Information for Adult NHL section of this summary for more information.)Treatment Option Overview for NHL During PregnancyTable 5. Treatment Options for NHL During PregnancyStageStandard Treatment OptionsIndolent NHL During PregnancyDelay treatment until after deliveryAggressive NHL During PregnancyImmediate therapyEarly delivery, when feasibleTermination of pregnancyIndolent NHL During PregnancyTreatment may be delayed for those women with an indolent NHL.Aggressive NHL During PregnancyImmediate therapyAccording to anecdotal case series, most NHLs in pregnant patients are aggressive,
Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment for Indolent, Recurrent Adult NHL
In general, treatment with standard agents rarely produces a cure in patients whose disease has relapsed. Sustained remissions after relapse can often be obtained in patients with indolent lymphomas, but relapse will usually ensue. Favorable survival after relapse has been associated with an age younger than 60 years, complete remission rather than partial remission, and duration of response longer than 1 year. Even the most favorable subset, however, has a tenfold greater mortality compared with age-adjusted U.S. population rates. Patients who experience a relapse with indolent lymphoma can often have their disease controlled with single agent or combination chemotherapy, rituximab (an anti-CD20 monoclonal antibody), lenalidomide, radiolabeled anti-CD20 monoclonal antibodies, or palliative radiation therapy.[2,3] Long-term freedom from second relapse, however, is uncommon and multiple relapses will usually occur. Patients with indolent lymphoma may experience a relapse with a
Cutaneous T-Cell Lymphomas
Important It is possible that the main title of the report Cutaneous T - Cell Lymphomas is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report. ...
Chronic Myeloproliferative Neoplasms Treatment (PDQ®): Treatment - Patient Information [NCI] - Stages of Chronic Myeloproliferative Neoplasms
There is no standard staging system for chronic myeloproliferative disorders.Staging is the process used to find out how far the cancer has spread. There is no standard staging system for chronic myeloproliferative disorders. Treatment is based on the type of myeloproliferative disorder the patient has. It is important to know the type in order to plan treatment.
Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment for Aggressive, Recurrent Adult NHL
Standard Treatment Options for Aggressive, Recurrent Adult NHLStandard treatment options for aggressive, recurrent adult non-Hodgkin lymphoma (NHL) include the following:Bone marrow or stem cell transplantation.Re-treatment with standard agents.Palliative radiation therapy.Bone marrow or stem cell transplantationBone marrow transplantation (BMT) is the treatment of choice for patients whose lymphoma has relapsed. Preliminary studies indicate that approximately 20% to 40% of patients will have a long-term disease-free status, but the precise percentage depends on patient selection and the specific treatment used. Preparative drug regimens have varied; some investigators also use total-body irradiation. Similar success has been achieved using autologous marrow, with or without marrow purging, and allogeneic marrow.[2,3,4,5,6]Evidence (BMT):In a prospective, randomized study, (EORTC-PARMA), 215 patients in first or second relapse of aggressive lymphoma, younger than 60 years, and
Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Get More Information From NCI
Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support
Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Patient Information [NCI] - Recurrent Adult Non-Hodgkin Lymphoma
Recurrent adult non-Hodgkin lymphoma is cancer that has recurred (come back) after it has been treated. The lymphoma may come back in the lymph system or in other parts of the body. Indolent lymphoma may come back as aggressive lymphoma. Aggressive lymphoma may come back as indolent lymphoma.
Childhood Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - High-Stage Childhood Anaplastic Large Cell Lymphoma Treatment
Children and adolescents with high-stage (stage III or IV) anaplastic large cell lymphoma have a disease-free survival of approximately 60% to 75%.[1,2,3,4,5,6] It is unclear which strategy is best for the treatment of high-stage anaplastic large cell lymphoma. The German Berlin-Frankfurt-Munster (BFM) group used six cycles of intensive pulsed therapy, similar to their B-cell non-Hodgkin lymphoma (NHL) therapy (GER-GPOH-NHL-BFM-90 [NHL-BFM-90]).; [Level of evidence: 1iiA] Building on these results, the European Intergroup for Childhood NHL (EICNHL) group conducted the FRE-IGR-ALCL99 study (based on the GER-GPOH-NHL-BFM-90 regimen). First, this randomized study demonstrated that methotrexate 1 g/m2 infused over 24 hours plus intrathecal methotrexate and methotrexate 3 g/m2 infused over 3 hours without intrathecal methotrexate yielded similar outcomes.[Level of evidence: 1iiC] However, methotrexate 3 g/m2 over 3 hours had less toxicity than methotrexate 1 g/m2 over 24